MB-106 Positioned as Potential CAR T-cell Therapy Option for Autoimmune Diseases

Manuel Litchman, MD, further discusses Mustang Bio's expansion into autoimmune diseases with MB-106, an autologous CAR T-cell therapy.

Related Keywords

Fred Hutch ,Manuel Litchman ,Fred Hutch Cancer Research Center ,Drug Administration ,Mustang Bio ,